We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Stem Cell Therapeutics Announces Completion of Enrollment in Key Modified REGENESIS Phase IIb Stroke Trial
News

Stem Cell Therapeutics Announces Completion of Enrollment in Key Modified REGENESIS Phase IIb Stroke Trial

Stem Cell Therapeutics Announces Completion of Enrollment in Key Modified REGENESIS Phase IIb Stroke Trial
News

Stem Cell Therapeutics Announces Completion of Enrollment in Key Modified REGENESIS Phase IIb Stroke Trial

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Stem Cell Therapeutics Announces Completion of Enrollment in Key Modified REGENESIS Phase IIb Stroke Trial"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Stem Cell Therapeutics Corp. has announced that it closed patient enrollment of the modified Phase IIb stroke trial on March 31st, 2010 and will analyze the data as they become available. Using a modified statistical approach the Company will analyze its trial data using the 96 patients that were enrolled.

Dr. Alan Moore, President and CEO, commented as follows:
"The modified REGENESIS-LED Phase IIb stroke trial enrolled 96 patients in six months which is a tremendous achievement. Despite our best recruitment efforts, however, we have not recruited any additional North America patients. The last patient in the trial was recruited at the end of January 2010. Using an alternate method of data analysis, with a proven track record (used in one of t-PA's pivotal phase III studies) will allow us to achieve our endpoint with fewer patients while staying on track with our previously reported time-line. We look forward to receiving the results of this clinical trial for the treatment of stroke patients with NTx(R)-265."

With the modified Phase IIb stroke trial closed, SCT anticipates to complete patient 90 day endpoint assessments by the end of April 2010 with data analysis to follow soon after.
Advertisement